Clinical Trial Update: An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy [Phase 2]

View source ↗

Summary

This document reports the completion of an open-label Phase IIa trial evaluating PRX302 for locally recurrent prostate cancer after primary radiation therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PRX302

Snippet

Sponsor: Sophiris Bio Corp | Conditions: Locally Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED